Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial

doi:10.6515/ACS.202103_37(2).20200914B

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23419

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23419

Title:	Extended-Release Carvedilol in the Treatment of Hypertension: A Double-Blind, Randomized, Placebo-Controlled Trial
Authors:	Wang, KL;Fang, CY;Lai, WT;Wang, TD;Ueng, KC;Wang, KY;Wang, JH;Shyu, KG;Chiang, CE
Keywords:	Carvedilol;Extended-release formulation;Hypertension
Date:	2021
Issue Date:	2022-08-05T09:36:58Z (UTC)
Publisher:	TAIWAN SOC CARDIOLOGY
ISSN:	1011-6842
Abstract:	Background: Immediate-release carvedilol requires twice-daily dosing and may have low treatment compliance. We assessed the efficacy of a new formulation of once-daily extended-release carvedilol (carvedilol ER) on systolic blood pressure (SBP) and diastolic blood pressure (DBP) among patients with hypertension in this double-blind, randomized, placebo-controlled trial. Methods: A total of 134 patients with untreated or uncontrolled hypertension were randomly assigned in a 1:1:1 ratio to receive placebo, low-dose carvedilol ER, or high-dose carvedilol ER for 8 weeks. The primary endpoint was the reduction in office SBP at 8 weeks. Secondary endpoints included the reduction in office DBP and the proportion of patients with blood pressure (BP) < 140/90 mm Hg. Results: In the intention-to-treat population, placebo-adjusted changes in SBP/DBP were -2.9 mm Hg [95% confidence interval (CI), -9.6 to 3.7]/-1.7 mm Hg (95% CI, -5.6 to 2.3) and -4.9 mm Hg (95% CI, -11.5 to 1.7)/-3.4 mm Hg (95% CI, -7.3 to 0.5) for low-dose carvedilol ER and high-dose carvedilol ER, respectively. In the per-protocol population, high-dose carvedilol ER was associated with a significant DBP reduction [placebo-adjusted difference, -4.7 mm Hg (95% CI, -8.8 to -0.5); adjusted p = 0.026]. There was a gradational improvement in BP control with carvedilol ER (25%, 37%, and 48% for placebo, low-dose carvedilol ER, and high-dose carvedilol ER, respectively; linear-by-linear association p = 0.028). There were no differences in safety among the three groups. Conclusions: Carvedilol ER, though well tolerated, did not result in a greater reduction in either SBP or DBP compared with placebo.
URI:	http://dx.doi.org/10.6515/ACS.202103_37(2).20200914B https://www.webofscience.com/wos/woscc/full-record/WOS:000629272300009 https://ir.csmu.edu.tw:8080/handle/310902500/23419
Relation:	ACTA CARDIOLOGICA SINICA ,2021,v37,issue 2, P186-194
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	149	View/Open

Loading...